Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up – Here’s Why

Posted by on Aug 18th, 2026

Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $14.33, but opened at $14.8864. Astellas Pharma shares last traded at $14.43, with a volume of 8,332 shares changing hands.

Analysts Set New Price Targets

Separately, Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold”.

Read Our Latest Stock Analysis on ALPMY

Astellas Pharma Trading Up 0.4%

The firm has a market cap of $26.04 billion, a P/E ratio of 10.95 and a beta of 0.08. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.90 and a current ratio of 1.17. The firm has a fifty day moving average of $13.60 and a 200-day moving average of $14.65.

Astellas Pharma Company Profile

(Get Free Report)

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).

Read More

Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.